Showing 5881-5890 of 8714 results for "".
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- Lutronic Rolls Out Derma V Dermatology Platformhttps://practicaldermatology.com/news/lutronic-rolls-out-derma-v-dermatology-platform/2460972/Lutronic is launching Derma V, a dermatology workstation that comprises a 532nm green laser, a 1064nm laser plus ICD cooling and IntelliTrack. "We created a device that brings the essential lasers that skin specialists need for their daily work - vascular, pigment and rejuvenation
- IFPA Calls for Action Against Psoriasishttps://practicaldermatology.com/news/ifpa-calls-for-action-against-psoriasis/2460971/Today is World Psoriasis Day, and the International Federation of Psoriasis Associations (IFPA) is launching a global petition to demand progress. In 2014, all UN nations unanimously voted to approve the Resolution on Psoriasis (WHA 67.9), committing to improve the l
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author
- Crown Aesthetics Launches SkinPen Precision Ambassador Programhttps://practicaldermatology.com/news/crown-aesthetics-launches-skinpen-precision-ambassador-program/2460968/Crown Aesthetics announced the launch of their SkinPen Ambassador Program in conjunction with National Microneedling Day. The SkinPen Ambassador Program presents current SkinPen providers with the opportunity to showcase their practice success and to share valuable insights and SkinPen
- Resilia Pharmaceuticals Obtains Marketing License for Solace Eczema Creamhttps://practicaldermatology.com/news/resilia-pharmaceuticals-obtains-marketing-license-for-solace-eczema-cream/2460967/Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. Previously only avai